S. Berthier

Pharmacokinetic and Pharmacodynamic Assessments of HMG‐CoA Reductase Inhibitors When Coadministered with Everolimus

J. Kovarik, Stefan Hartmann, C. Rordorf, 2002, Journal of clinical pharmacology.

PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO

M. Zollinger, J. Baldeck, A. Schweitzer, 2006, Drug Metabolism and Disposition.

Clinical Development of an Everolimus Pediatric Formulation: Relative Bioavailability, Food Effect, and Steady‐State Pharmacokinetics

J. Kovarik, C. Rordorf, A. Noè, 2003, Journal of clinical pharmacology.

Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications

J. Kovarik, C. Rordorf, Chyi-Hung Hsu, 2001, Clinical pharmacology and therapeutics.

Pharmacokinetics of an Everolimus‐Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

J. Kovarik, B. Kaplan, J. Dantal, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

FTY720 and Cyclosporine: Evaluation for a Pharmacokinetic Interaction

A. Gottlieb, J. Kovarik, R. Schmouder, 2004, The Annals of pharmacotherapy.